One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) declared that its Board of Directors has approved a stock buyback program on Monday, December 9th, RTT News reports. The company plans to repurchase ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
CBS News reports that workplace violence at Allina Health's Abbott Northwestern Hospital has led to more than $83,000 in fines over the past year. Other news from the health industry is on the demand ...
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly ...
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are currently covering the stock, Marketbeat Ratings ...